RaySearch Receives Order for RayStation and RayCare in Italy

RaySearch Laboratories AB (publ) announces that Ion Beam Applications S.A. (IBA), market leader in proton therapy, has placed an order for RayStation®* treatment planning system and the oncology information system RayCare®* for installation at CRO National Cancer Institute (C.R.O.) in Aviano, Italy. RaySearch partnered with IBA for the public tender, with IBA serving as the main system integrator.

The order includes implementation of both RayStation and RayCare at C.R.O. Aviano. The combination of RayStation and RayCare provides an integrated and unified solution throughout the complete workflow, when combined with an IBA proton therapy machine. 

IBA signed the contract with C.R.O. Aviano in November 2021 following a comprehensive vendor selection process. RaySearch partnered with IBA for the public tender and the center has now decided to select RayStation and RayCare. RayStation includes a complete set of licencs for pencil beam scanning, including automatic proton therapy planning using machine learning techniques. RayCare includes licences to cover the workflow management and the treatment delivery for all patients treated with proton therapy.

C.R.O. Aviano is expected to start treating patients by the end of 2024.

Johan Löf, founder and CEO, RaySearch, says: “We are very pleased to provide C.R.O. Aviano with RayStation and RayCare. The adoption of both RaySearch solutions at C.R.O. Aviano will enhance implementation efficiency as well as the possibility to optimize clinical excellence of proton therapy at this center. For RaySearch, this agreement further strengthens our prominent role in both treatment planning and oncology information systems for proton therapy centers in Europe.”

The total order value is EUR 1.7 million (approximately SEK 19 million). A service contract is not included but is expected to be added at a later stage.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy